Composition: It is a fixed-dose combination of the long-acting amylin analog Cagrilintide and the glucagon-like peptide-1 receptor agonist Semaglutide.

Mechanism of action: Cagrilintide, as an amylin receptor agonist, can significantly suppress appetite and effectively delay gastric emptying; Semaglutide, as a GLP-1 receptor agonist, can significantly enhance insulin secretion and strongly inhibit the release of glucagon.

At the same time, it further slows gastric emptying. The combination of the two is excellent in blood sugar control and weight management.